In last trading session, Lyell Immunopharma Inc (NASDAQ:LYEL) saw 0.79 million shares changing hands with its beta currently measuring -0.31. Company’s recent per share price level of $0.41 trading at $0.01 or 3.31% at ring of the bell on the day assigns it a market valuation of $122.57M. That closing price of LYEL’s stock is at a discount of -602.44% from its 52-week high price of $2.88 and is indicating a premium of 4.88% from its 52-week low price of $0.39. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.69 million shares which gives us an average trading volume of 808.36K if we extend that period to 3-months.
For Lyell Immunopharma Inc (LYEL), analysts’ consensus is at an average recommendation of Hold while assigning it a mean rating of 3.33. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 3 suggested the stock as a Hold whereas 0 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Lyell Immunopharma Inc (NASDAQ:LYEL) trade information
Upright in the green during last session for gaining 3.31%, in the last five days LYEL remained trading in the green while hitting it’s week-highest on Wednesday, 05/14/25 when the stock touched $0.41 price level, adding 8.13% to its value on the day. Lyell Immunopharma Inc’s shares saw a change of -35.16% in year-to-date performance and have moved 3.75% in past 5-day. Lyell Immunopharma Inc (NASDAQ:LYEL) showed a performance of -5.47% in past 30-days. Number of shares sold short was 5.66 million shares which calculate 7.97 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 7 to the stock, which implies a rise of 94.14% to its current value. Analysts have been projecting 1 as a low price target for the stock while placing it at a high target of 12. It follows that stock’s current price would drop -143.9% in reaching the projected high whereas dropping to the targeted low would mean a loss of -143.9% for stock’s current value.
Lyell Immunopharma Inc (LYEL) estimates and forecasts
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -19.90% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 45.54% while estimates for its earnings growth in next 5 years are of 27.14%.
Lyell Immunopharma Inc (NASDAQ:LYEL)’s Major holders
Insiders are in possession of 13.73% of company’s total shares while institution are holding 66.41 percent of that, with stock having share float percentage of 76.98%. Investors also watch the number of corporate investors in a company very closely, which is 66.41% institutions for Lyell Immunopharma Inc that are currently holding shares of the company. MWG MANAGEMENT LTD. is the top institutional holder at LYEL for having 20.16 million shares of worth $29.24 million. And as of 2024-06-30, it was holding 7.8945 of the company’s outstanding shares.
The second largest institutional holder is ORLAND PROPERTIES LTD, which was holding about 15.09 million shares on 2024-06-30. The number of shares represents firm’s hold over 5.91 of outstanding shares, having a total worth of $21.89 million.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and T. Rowe Price Health Sciences Fund, Inc. are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 5.64 shares of worth $2.34 million or 1.91% of the total outstanding shares. The later fund manager was in possession of 4.94 shares on Dec 31, 2024 , making its stake of worth around $2.05 million in the company or a holder of 1.67% of company’s stock.
